Results 231 to 240 of about 195,947 (275)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 2019
Visceral Leishmaniasis ...
Loscocco G. G, Piccini M.
openaire +2 more sources
Visceral Leishmaniasis ...
Loscocco G. G, Piccini M.
openaire +2 more sources
Treatment of visceral leishmaniasis
Expert Opinion on Pharmacotherapy, 2005The Leishmania donovani complex includes L. chagasi and L. infantum, and causes visceral leishmaniasis (VL), a disseminated and potentially fatal form of leishmaniasis. The treatment options for VL are limited. Pentavalent antimonials (Sbv) are the first-line treatment options worldwide except for in Europe and Sbv-unresponsive regions of India ...
Shyam, Sundar, Madhukar, Rai
openaire +2 more sources
Visceral leishmaniasis in paediatrics
Current Opinion in Infectious Diseases, 2002Visceral leishmaniasis is a vector-borne systemic infection, which affects half a million people each year in many areas of the world. Typical disease manifests with fever, hepatosplenomegaly, pancytopenia, and progressive deterioration of the host. Although molecular methods appear promising as a non-invasive diagnostic tool, definite diagnosis still ...
Dimitris A, Kafetzis, Helen C, Maltezou
openaire +2 more sources
- Amphotericin B: A drug of choice for Visceral Leishmaniasis.
Acta Tropica, 2022S. Kumari +5 more
semanticscholar +1 more source
Mediterranean Visceral Leishmaniasis in Pregnancy
Scandinavian Journal of Infectious Diseases, 1994Visceral leishmaniasis (VL) in pregnancy is rare in Mediterranean countries. We report here 2 cases of VL in pregnant women who acquired the infection in Italy. In the first case, the disease was diagnosed and treated with liposomal amphotericin B during the pregnancy.
GRADONI L +4 more
openaire +3 more sources